Skip to main content

β3-Adrenergic Receptor Agonists

β3-adrenergic receptor agonists are the contemporary companion class to antimuscarinics for overactive bladder (OAB) — working through the opposite arm of autonomic bladder physiology. Two agents are FDA-approved: mirabegron (Myrbetriq) and vibegron (Gemtesa). Both stimulate β3-adrenoceptors in the detrusor muscle to relax the detrusor during storage, increase functional bladder capacity, and reduce urgency — with efficacy comparable to antimuscarinics but a substantially better tolerability profile (no anticholinergic burden, no dementia association).[1][2][3]

The 2024 AUA/SUFU OAB guideline positions β3-agonists as first-line OAB pharmacotherapy alongside antimuscarinics, with a modest preference for β3-agonists in patients at risk for anticholinergic side effects.[4]

Mechanism of Action​

β3-adrenoceptors are highly expressed in the detrusor muscle. Stimulation activates adenylyl cyclase → cAMP production, producing:[2][3][5]

  • Direct detrusor smooth muscle relaxation during the storage phase
  • Decreased afferent signaling from the bladder
  • Improved bladder compliance during filling
  • Increased functional bladder capacity
  • Suppression of detrusor micro-contractions via effects on detrusor smooth muscle cells and suburothelial interstitial cells

Secondary mechanism — cholinergic inhibition​

Recent work has identified a prejunctional effect: β3 stimulation activates an EPAC1/PKC pathway that promotes adenosine release, providing additional cholinergic inhibition of parasympathetic nerves at the neuromuscular junction — a second, additive mechanism beyond direct smooth muscle relaxation.[6]

This multi-level mechanism helps explain why β3-agonists achieve efficacy comparable to antimuscarinics despite acting on a different receptor family.

FDA-Approved Agents​

Mirabegron (Myrbetriq)​

First-in-class — FDA-approved 2012.[7]

PropertyDetail
IndicationsOAB (adults); neurogenic detrusor overactivity in pediatric patients age ≥3 years
Adult dosingStart 25 mg PO daily; can increase to 50 mg after 4–8 weeks
Pediatric dosingWeight-based; granule or tablet formulations
Onset of efficacy4–8 weeks; sustained through 52 weeks
Key cautionsSevere uncontrolled HTN — not recommended; ESRD — not recommended; significant hepatic impairment — not recommended
Drug interactionsCYP2D6 inhibitor — caution with metoprolol, desipramine, flecainide

Vibegron (Gemtesa)​

FDA-approved 2020 (OAB); 2024 expansion to OAB in men on BPH pharmacotherapy (COURAGE trial).[8][9]

PropertyDetail
IndicationsOAB (adults); OAB in adult males on BPH pharmacologic therapy (α-blocker ± 5-ARI)
Dose75 mg PO daily (no titration required)
Onset of efficacyWithin 4 weeks; sustained 52+ weeks
BP effectsMinimal — ambulatory BP monitoring shows no clinically meaningful changes[10]
Drug interactionsMinimal vs. mirabegron; no CYP2D6 concern

Clinical Efficacy​

Mirabegron — phase 3 data[1][7][11]​

OutcomeMirabegron 50 mgPlacebo
Micturition frequency reduction−1.6 to −1.9 episodes / 24 h−1.0 to −1.3
Incontinence reduction−1.4 to −1.6 episodes / 24 h−1.1 to −1.2
Volume per void+12 to +24 mL+7 to +12 mL

Network meta-analysis: mirabegron 50 mg has comparable overall efficacy to most antimuscarinics, with significantly better tolerability on dry mouth (better than 21/22 active comparators), constipation (9/20), and urinary retention (7/10).[12]

Vibegron — EMPOWUR trial (1,518 patients)[8][13]​

OutcomeVibegron 75 mgPlacebo
Micturition frequency reduction−1.8 episodes / 24 h−1.3
Incontinence reductionSignificantly greater than placebo (P<0.001)—
Volume per voidSignificantly greater increase (P<0.001)—
Durable effectSustained through 52 weeks—

Vibegron vs. mirabegron​

Head-to-head direct comparison is limited, but:

  • Indirect treatment comparison (Kennelly 2021): vibegron may have slightly greater efficacy for total incontinence episodes at 4 and 52 weeks and volume voided at 12 and 52 weeks[14]
  • 2025 network meta-analysis (Huang): vibegron outperformed mirabegron and antimuscarinics in reducing micturition frequency; vibegron 100 mg (dose higher than FDA-approved 75 mg) showed the greatest reduction[15]
  • Clinically, the two agents are largely interchangeable with a modest edge to vibegron on dosing simplicity (75 mg daily, no titration) and drug-interaction profile

Special Populations​

Men with BPH — the COURAGE trial​

Vibegron's 2024 FDA expansion for OAB in men on BPH therapy is backed by the COURAGE trial (1,105 men on α-blocker ± 5-ARI):[9]

Outcome at 12 weeksVibegron effect
Daily micturitions−0.74 (P<0.001)
Urgency episodesSignificantly reduced vs. placebo
IPSS-storage subscoreSignificantly improved vs. placebo
Retention / safetyComparable to placebo

This is the first β3-agonist approved specifically for the "prostate-with-OAB" phenotype — a common clinical scenario where antimuscarinics are often avoided due to retention concerns.

Elderly population​

  • Real-world data: β3-agonist recipients tend to be older (mean age 77.4 years for mirabegron vs. 69.2 for antimuscarinics)[16]
  • Reflects preference for β3-agonists in patients vulnerable to anticholinergic side effects
  • No dementia signal associated with β3-agonists

Pediatric NDO​

Mirabegron is FDA-approved for neurogenic detrusor overactivity in pediatric patients age ≥3 years — weight-based dosing with granule formulation.

Neurogenic LUT dysfunction​

Both agents used off-label (vibegron) and on-label (mirabegron pediatric NDO) in adult NLUTD. Effective at reducing detrusor pressures and improving compliance; frequently combined with antimuscarinics for refractory storage dysfunction.

Adverse Effects​

Common[1][8][13][17]​

AEMirabegronVibegron
Hypertension8–9% (mild SBP ↑ 3–10 mm Hg at high doses)Minimal (ABPM: no clinically meaningful change)
UTI2–7%2–7%
Headache2–6%2–6%
Nasopharyngitis2–11%2–11%
Dry mouth1.7–2% (placebo-level; vs. 5% for antimuscarinics)Placebo-level
ConstipationLower than antimuscarinicsLower than antimuscarinics
Discontinuation for AELow1.7–2.4% (lower than tolterodine 3.3%)

Serious / unexpected adverse effects (pharmacovigilance)​

Post-marketing FDA FAERS data on mirabegron identified rare but flagged signals:[18]

  • Cardiac arrhythmias — atrial fibrillation, tachycardia, palpitations
  • Neurological events — reports of dementia, TIA, Parkinson's disease (signals; causality uncertain)
  • Vascular — ANCA-positive vasculitis (very rare)
  • Angioedema — lip / tongue swelling

Urinary retention​

Japanese JADER adverse event database analysis showed urinary retention as the most frequently reported AE:[19]

  • Mirabegron crude ROR: 62.1
  • Vibegron crude ROR: 250
  • Risk higher with: concomitant antimuscarinic, men with BPH, first 15 days of treatment

The COURAGE trial data in men on BPH therapy suggest this risk is manageable with appropriate selection — vibegron is now specifically approved for this population.

Cardiovascular safety​

Vibegron specifically: dedicated ambulatory BP monitoring studies demonstrate no clinically meaningful effects on BP or HR.[10][20] EMPOWUR: hypertension incidence with vibegron 1.7% vs. placebo 1.7%.

Mirabegron: small but detectable BP increases (SBP ↑ 3–10 mm Hg at doses 50–200 mg); monitor BP periodically.

Contraindications and Precautions​

Mirabegron[21]​

Not recommended for:

  • Severe uncontrolled hypertension
  • End-stage renal disease
  • Significant hepatic impairment
  • CYP2D6 drug interactions (metoprolol, desipramine, flecainide, thioridazine) — reduce dose or choose alternative

Vibegron​

  • No specific renal or hepatic restrictions at standard dose
  • Minimal drug interactions
  • No CYP2D6 concern

General precautions​

  • BP monitoring — particularly for mirabegron, particularly in hypertensive patients
  • Urinary retention risk assessment — consider baseline PVR in men with BPH; particularly in the first 15 days of treatment
  • Concomitant antimuscarinic — increases retention risk

Combination Therapy​

Mirabegron 25–50 mg + solifenacin 5 mg provides superior efficacy vs. either agent alone for patients with suboptimal monotherapy response.[12][15][22] The trade-off: increased anticholinergic side effects (dry mouth, constipation) compared with β3-agonist monotherapy.

  • BESIDE and SYNERGY trials established efficacy of the combination
  • Stable option for patients whose OAB symptoms are not fully controlled on a single agent
  • Less-commonly used combinations (mirabegron + other antimuscarinics, vibegron + antimuscarinic) appear to have similar synergy based on mechanism

Clinical Positioning​

2024 AUA/SUFU framework[4]​

β3-agonists are positioned as:

  • First-line OAB pharmacotherapy alongside antimuscarinics
  • Preferred option for patients at risk for anticholinergic side effects:
    • Elderly
    • Cognitive impairment
    • Dry-mouth intolerance
    • Constipation-prone
    • Narrow-angle glaucoma
    • Men with BPH at risk for retention (vibegron FDA-approved for this population)
  • Alternative when antimuscarinics are contraindicated or not tolerated
  • Add-on therapy for patients with inadequate response to antimuscarinics

Progression to advanced therapy​

If symptoms don't respond to β3-agonist + antimuscarinic (mono or combined), consider:

  • Intradetrusor onabotulinumtoxinA (100 U idiopathic OAB; 200 U NLUTD)
  • Sacral neuromodulation (InterStim, Axonics)
  • Posterior tibial nerve stimulation (PTNS, eCoin, Revi)

See Also​

References​

1. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men. JAMA. 2025;334(9):809–821. doi:10.1001/jama.2025.7045

2. Andersson KE, Martin N, Nitti V. Selective β3-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013;190(4):1173–80. doi:10.1016/j.juro.2013.02.104

3. Igawa Y, Aizawa N, Michel MC. β3-adrenoceptors in the normal and diseased urinary bladder — what are the open questions? Br J Pharmacol. 2019;176(14):2525–2538. doi:10.1111/bph.14658

4. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11–20. doi:10.1097/JU.0000000000003985

5. Hennenberg M, Michel MC. Adrenoceptors in the lower urinary tract. Handb Exp Pharmacol. 2024;285:333–367. doi:10.1007/164_2023_678

6. Silva I, Magalhães-Cardoso MT, Ferreirinha F, et al. β adrenoceptor-induced cholinergic inhibition in human and rat urinary bladders involves the exchange protein directly activated by cyclic AMP 1 favoring adenosine release. Br J Pharmacol. 2020;177(7):1589–1608. doi:10.1111/bph.14921

7. Food and Drug Administration. Myrbetriq (mirabegron) prescribing information. Updated 2024-08-01.

8. Staskin D, Frankel J, Varano S, et al. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–324. doi:10.1097/JU.0000000000000807

9. Staskin D, Owens-Grillo J, Thomas E, et al. Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol. 2024;212(2):256–266. doi:10.1097/JU.0000000000003999

10. Frankel J, Staskin D, Varano S, et al. An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder. Ther Clin Risk Manag. 2022;18:171–182. doi:10.2147/TCRM.S310371

11. Deeks ED. Mirabegron: a review in overactive bladder syndrome. Drugs. 2018;78(8):833–844. doi:10.1007/s40265-018-0924-4

12. Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–333. doi:10.1016/j.eururo.2018.03.020

13. Staskin D, Frankel J, Varano S, et al. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol. 2021;205(5):1421–1429. doi:10.1097/JU.0000000000001574

14. Kennelly MJ, Rhodes T, Girman CJ, et al. Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison. Adv Ther. 2021;38(11):5452–5464. doi:10.1007/s12325-021-01902-8

15. Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025. doi:10.1007/s00228-025-03855-1

16. Huang CK, Lin CC, Lin AT. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. Sci Rep. 2020;10(1):11355. doi:10.1038/s41598-020-68170-4

17. Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119–128. doi:10.1016/j.eururo.2019.09.024

18. Wang J, Zhang A, Ye M, Zhang C. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA Adverse Event Reporting System (FAERS) database. Front Pharmacol. 2024;15:1376535. doi:10.3389/fphar.2024.1376535

19. Kawazoe T, Ishida T, Jobu K, et al. Analysis of urinary retention caused by selective β3-adrenoceptor agonists using the Japanese Adverse Drug Event Report database (JADER). Pharmazie. 2023;78(5):56–62. doi:10.1691/ph.2023.3509

20. Peyronnet B, Brucker BM, De Nunzio C, et al. Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes. World J Urol. 2025;43(1):514. doi:10.1007/s00345-025-05799-8

21. American College of Obstetricians and Gynecologists. Practice Bulletin No. 155: Urinary incontinence in women. Obstet Gynecol. 2015;126(5):e66–e81. doi:10.1097/AOG.0000000000001148

22. Jiang YH, Kuo HC. Current optimal pharmacologic therapies for overactive bladder. Expert Opin Pharmacother. 2023;24(18):2005–2019. doi:10.1080/14656566.2023.2264183